The ASCO Gastrointestinal Cancers 2025 Symposium, being held from January 23rd-25th in Moscone West, San Francisco, brings together top experts in gastrointestinal oncology.
The 2025 ASCO GI Cancers Symposium showcases the latest innovative science, solution-focused strategies, and multidisciplinary approaches in GI cancer treatment, research, and care. Attendees are able to share experiences, reconnect with colleagues, discuss translational research needs, and build new research collaborations. The symposium features a main session room and offers three days of focused sessions across all GI cancer disease sites and treatment modalities. Participants can discover the latest developments in GI scientific research that will have an immediate impact on treatment decisions.
Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, shared about this conference on social media:
A phase 2/3 study of evorpacept
“A phase 2/3 study of evorpacept, a CD47 myeloid IC, in HER2 plus GC/GEJ cancer
- ASPEN-06 phs 2: Final analysis
- ORR 40.3% vs 26.6%
- mPFS 7.4 vs 7.5 mo
- Higher efficacy in patients with fresh biopsy
Looks promising, confirm Her2 status after targeted therapy.”
Albumin-bound docetaxel vs. docetaxel in advanced GEJ cancer
“Albumin-bound docetaxel vs. docetaxel in advanced gGC/GEJ cancer
Phs II study
- ORR 21 vs 14%
- mPFS 4 vs 2.7 mo
- mOS 11.3 vs 7.8 mo
- TEASs ≥340% vs 38%
Looks effective, manageable AEs, Phs-3 ongoing.”
“Camrelizumab plus Nab-POF in initially unresectable locally GC/GEJ cancer
Phase 3 DRAGON-01 trial, 2:1, 222 patients
- R0 resection: 75%, pCR 23%
- 3 year OS rate 62%
- AEs ≥3° 42%
High conversion rate…”
Outcomes of patients with peritoneal-limited metastatic gastric cancer
“Outcomes of patients with peritoneal-limited metastatic gastric cancer undergoing bidirectional CTx cytoreductive surgery with HIPEC.
PRECISE-SG 1, single center RWD
- mPFS 9.5
- mOS 17.5 mo
- Surgery associated with better OS.”
Gasteric cancer with peritoneal metastasis
“Intraperitoneal plus i.v. paclitaxel/S-1 vs i.v. paclitaxel/ S-1 in GC with peritoneal metastasis.
Phase 3 DRAGON-01 trial, 2:1, 222 patients
- Conversion surgery 50% vs 35%
- mOS 19.4 vs 13.9 mo
IP CTx improves outcome, no ICI used, global study?.”
Treatment of esophageal squamous cell carcinoma
“CTx plus sintilimab vs chemoradiotherapy plus sintilimab vs chemoradiotherapy for neoadjuvant treatment in resectable locally advanced esophageal squamous cell carcinoma.
PHS III SCIENCE trial
- pCR: 13 vs 47.3 vs 60%
- More TEAEs in group B
Adding ICI to nCRT looks effective, manageable AEs.”
EORTC-1203 GITC INNOVATION trial results
“Trastuzumab with or without pertuzumab for peri-op CTx of HER-2 plus GC.
EORTC-1203 GITC INNOVATION
- mpRR: 23 vs 37 vs 26%
- 3year OS rate: 75 vs 76 vs 65%
- High Tox for CTx + T + P
Negative trial, but high mpRR by adding T to CTx.”
